{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis%2C+Chronic&page=17", "query": { "condition": "Hepatitis, Chronic", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 696, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis%2C+Chronic&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis%2C+Chronic&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T15:01:56.955Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00623428", "title": "A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2008-06", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-07-22", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 38, "location_summary": "Birmingham, Alabama • La Jolla, California • Lancaster, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00623428" }, { "nct_id": "NCT00507689", "title": "Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Hepatitis B Immunoglobulin (HBIg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2007-09", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2014-03-14", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00507689" }, { "nct_id": "NCT03093740", "title": "Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Failure Chronic", "Hepatitis C" ], "interventions": [ { "name": "Zepatier", "type": "DRUG" }, { "name": "Zepatier plus Sofosbuvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2018-10-01", "completion_date": "2021-01-31", "has_results": false, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03093740" }, { "nct_id": "NCT03685708", "title": "HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis", "Safety and Tolerability" ], "interventions": [ { "name": "HEPLISAV-B", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 78, "start_date": "2018-12-07", "completion_date": "2020-12-16", "has_results": true, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03685708" }, { "nct_id": "NCT00117676", "title": "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TDF", "type": "DRUG" }, { "name": "ADV", "type": "DRUG" }, { "name": "TDF placebo", "type": "DRUG" }, { "name": "ADV placebo", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 382, "start_date": "2005-02", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 17, "location_summary": "La Jolla, California • Pasadena, California • San Diego, California + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00117676" }, { "nct_id": "NCT00085917", "title": "Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HIV Infections" ], "interventions": [ { "name": "Double dose pegylated interferon with weight based Ribavirin", "type": "DRUG" }, { "name": "standard dose pegylated interferon alfa -2a and ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2004-06", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2011-06-27", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085917" }, { "nct_id": "NCT01525628", "title": "Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "midazolam", "type": "DRUG" }, { "name": "BI 201335", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "tolbutamide", "type": "DRUG" }, { "name": "pegylated interferon", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 72, "start_date": "2012-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-06-10", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 5, "location_summary": "La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525628" }, { "nct_id": "NCT03577171", "title": "A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "ABI-H0731", "type": "DRUG" }, { "name": "SOC ETV", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Assembly Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 25, "start_date": "2018-06-19", "completion_date": "2019-06-21", "has_results": true, "last_update_posted_date": "2021-01-28", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 7, "location_summary": "Coronado, California • Los Angeles, California • San Diego, California + 4 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03577171" }, { "nct_id": "NCT02350569", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2015-05-22", "completion_date": "2016-04-22", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 6, "location_summary": "San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02350569" }, { "nct_id": "NCT02166047", "title": "Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "Vesatolimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 162, "start_date": "2014-06-30", "completion_date": "2016-10-20", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-11-15T15:01:56.955Z", "location_count": 9, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT02166047" } ] }